Shanghai C&D Innostic Medical Technology 建发致新
9 significant filings since 30 May 2026: 4 on guarantee or financial assistance, 2 on new listing and 1 on dividend, and 2 other kinds. The latest, on 22 Sep 2026: 关于部分首次公开发行前已发行股份及首次公开发行战略配售股份上市流通提示性公告. On 15 Jul 2026 the company said it expects net profit for the period ending 30 Jun 2026 to rise by 2.16% to 16.76% from the same period a year earlier.
自 30 May 2026 起有 9 份重大公告：guarantee or financial assistance 4 份、new listing 2 份、dividend 1 份，另有 2 类。最新一份（22 Sep 2026）：关于部分首次公开发行前已发行股份及首次公开发行战略配售股份上市流通提示性公告。15 Jul 2026 公司预告截至 30 Jun 2026 的净利润较上年同期上升 2.16% 至 16.76%。
The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平：同期 99.3% 的评级为买入或跑赢。 Every rated report on this company said Buy or Outperform.
No broker has changed its rating on this company in the reports held.
| Broker 券商 | Analyst 分析师 | Latest Rating 最新评级 | Date 日期 | Reports 研报 | Target 目标价 |
|---|---|---|---|---|---|
| 东莞证券 | 谢雄雄 | Outperform 增持 | 24 Dec 2025 | 1 | — |
Each row is a broker's latest report in the last twelve months. A price target is given in 0 of 1 report. 每行为该券商近十二个月的最新研报；1 份中 0 份给出目标价。
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。